Tests tulisokibart for radiographic axial spondyloarthritis, a type of arthritis
Tests tulisokibart against placebo in adults with spine and pelvis arthritis.
Plain-language title generated from the registry record
Registry title: A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Key facts
- Where
- Amsterdam, Heerlen, and Rotterdam, NetherlandsSee the 3 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with radiographic axial spondyloarthritis (ankylosing spondylitis) who have active disease. They must have had a poor response to, or could not tolerate, NSAID pain medicines.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Radiographic axial spondyloarthritis (ankylosing spondylitis) with damage that shows on X-ray, active disease at screening and at randomization, and at least 3 months of back pain with symptoms starting before age 45.
- Earlier treatment
- Poor response to, or intolerance of, NSAIDs. Either no earlier biologic DMARD, or poor response to or intolerance of up to 2 classes of biologic DMARDs.
Main reasons for not taking part
- Any arthritis starting before age 17, or another inflammatory joint disease such as rheumatoid arthritis, lupus or psoriatic arthritis
- Cancer in the last 5 years (except fully treated non-melanoma skin cancer or cervical carcinoma in situ)
- Any active infection
- Known allergy or intolerance to tulisokibart or its ingredients
Read by machine on 11 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07133633, who can take part
Where in Netherlands
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
- Zuyderland Medisch Centrum StichtingHeerlen, NetherlandsTaking people
- Maasstad Ziekenhuis StichtingRotterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Merck Sharp & Dohme LLC
- Trial code
- NCT07133633EU 2025-521059-21-00
- Record updated
- 23 October 2026
- Original description
Researchers are looking for new ways to treat radiographic axial spondyloarthritis (r-axSpA). R-axSpA is a type of arthritis that causes pain, stiffness, and inflammation (swelling) in the spine and joints in the pelvis (hip bone). Radiographic means the damage it causes can be seen on X-rays.Read full original descriptionShow less
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)
Researchers are looking for new ways to treat radiographic axial spondyloarthritis (r-axSpA). R-axSpA is a type of arthritis that causes pain, stiffness, and inflammation (swelling) in the spine and joints in the pelvis (hip bone). Radiographic means the damage it causes can be seen on X-rays.
This study will help find out if a study medicine called tulisokibart can treat symptoms of r-axSpA. Researchers will look at different doses of tulisokibart.
Researchers want to know if at least one of the study doses of tulisokibart works better than a placebo to improve r-axSpA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.
Inclusion: The main inclusion criteria include but are not limited to the following:; Has a clinical diagnosis of axial spondyloarthritis (axSpA) and meets the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA including ≥3 months of back pain with age at symptom onset <45 years; Meets the radiographic criterion of the modified New York criteria for ankylosing spondylitis (AS) as determined by central reading at Screening; Has active disease at Screening and Randomization; Has a history of inadequate response (IR)/intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs) and is biologic disease-modifying antirheumatic drug (bDMARD)-naive, or has a history of IR/intolerance to up to a maximum of 2 bDMARD classes.
Exclusion: Has a history of cancer (except fully treated non-melanoma skin cancers or cervical carcinoma in situ after complete surgical removal) within the last 5 years; Has any active infection; Has known allergies, hypersensitivity, or intolerance to tulisokibart or its excipients; Has any arthritis with onset before age 17 years or current diagnosis of inflammatory joint disease other than radiographic axial spondyloarthritis (r-axSpA) (such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis (PsA), systemic sclerosis, myositis, etc.), or any other conditions that may, in the judgment of the investigator, interfere with the assessment of r-axSpA; The main exclusion criteria include but are not limited to the following:.